These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 17445912

  • 1. Ecchymoses as an adverse effect of fluoxetine treatment.
    Fountoulakis KN, Samolis S, Iacovides A, St Kaprinis G.
    Psychiatry Res; 2007 Jul 30; 152(1):91-2. PubMed ID: 17445912
    [Abstract] [Full Text] [Related]

  • 2. A Case of Fluoxetine-Induced Lower Extremity Ecchymosis.
    Çetin B, Ergelen M.
    Prim Care Companion CNS Disord; 2017 Jun 15; 19(3):. PubMed ID: 28636812
    [No Abstract] [Full Text] [Related]

  • 3. Fluoxetine-induced mania in an Asian patient.
    Pae CU, Lee CU, Lee SJ, Lee C, Paik IH.
    Psychiatry Clin Neurosci; 2004 Aug 15; 58(4):448-9. PubMed ID: 15298662
    [No Abstract] [Full Text] [Related]

  • 4. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse.
    Iovieno N, van Nieuwenhuizen A, Clain A, Baer L, Nierenberg AA.
    Depress Anxiety; 2011 Feb 15; 28(2):137-44. PubMed ID: 21284066
    [Abstract] [Full Text] [Related]

  • 5. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
    Papakostas GI, Petersen T, Homberger CH, Green CH, Smith J, Alpert JE, Fava M.
    Ann Clin Psychiatry; 2007 Feb 15; 19(1):5-8. PubMed ID: 17453655
    [Abstract] [Full Text] [Related]

  • 6. Complex movement disorders induced by fluoxetine.
    Bharucha KJ, Sethi KD.
    Mov Disord; 1996 May 15; 11(3):324-6. PubMed ID: 8723152
    [Abstract] [Full Text] [Related]

  • 7. Dysfunctional attitudes and perceived stress predict depressive symptoms severity following antidepressant treatment in patients with chronic depression.
    Pedrelli P, Feldman GC, Vorono S, Fava M, Petersen T.
    Psychiatry Res; 2008 Dec 15; 161(3):302-8. PubMed ID: 18976817
    [Abstract] [Full Text] [Related]

  • 8. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients.
    Gałecki P, Szemraj J, Bieńkiewicz M, Zboralski K, Gałecka E.
    Hum Psychopharmacol; 2009 Jun 15; 24(4):277-86. PubMed ID: 19319921
    [Abstract] [Full Text] [Related]

  • 9. Fluoxetine associated with thrombocytopenia and treatment with reboxetine: 3 cases.
    Yucel A, Yucel N, Ozcan H, Gulec M, Aydin A.
    J Clin Psychopharmacol; 2015 Jun 15; 35(3):354-5. PubMed ID: 25822478
    [No Abstract] [Full Text] [Related]

  • 10. The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder.
    Gudayol-Ferré E, Herrera-Guzmán I, Camarena B, Cortés-Penagos C, Herrera-Abarca JE, Martínez-Medina P, Cruz D, Hernández S, Genis A, Carrillo-Guerrero MY, Avilés Reyes R, Guàrdia-Olmos J.
    J Affect Disord; 2010 Dec 15; 127(1-3):343-51. PubMed ID: 20584552
    [Abstract] [Full Text] [Related]

  • 11. Transient psychosis with psychogenic polydipsia in schizotypal patient taking fluoxetine.
    Gutkovich Z, Rosenthal RN, Bogdonoff L.
    Psychosomatics; 1998 Dec 15; 39(3):295-6. PubMed ID: 9664779
    [No Abstract] [Full Text] [Related]

  • 12. [Secondary dermatologic effects of serotonin reuptake inhibitor antidepressants: hypothesis of cross-reacting allergy. Apropos of 2 cases].
    Beauquier B, Fahs H.
    Encephale; 1998 Dec 15; 24(1):62-4. PubMed ID: 9559306
    [Abstract] [Full Text] [Related]

  • 13. [SIADH with epileptic seizures and coma in fluoxetine therapy].
    Romerio SC, Radanowicz V, Schlienger RG.
    Praxis (Bern 1994); 2000 Mar 02; 89(10):404-10. PubMed ID: 10731855
    [Abstract] [Full Text] [Related]

  • 14. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Papakostas GI, McGrath P, Stewart J, Charles D, Chen Y, Mischoulon D, Dording C, Fava M.
    Psychiatry Res; 2008 Oct 30; 161(1):116-20. PubMed ID: 18755514
    [Abstract] [Full Text] [Related]

  • 15. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
    Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, Hirschowitz J.
    Int Clin Psychopharmacol; 2008 Sep 30; 23(5):269-75. PubMed ID: 18703936
    [Abstract] [Full Text] [Related]

  • 16. Cognitive behavioral therapy and fluoxetine for binge eating disorder: two-year follow-up.
    Devlin MJ, Goldfein JA, Petkova E, Liu L, Walsh BT.
    Obesity (Silver Spring); 2007 Jul 30; 15(7):1702-9. PubMed ID: 17636088
    [Abstract] [Full Text] [Related]

  • 17. Vulnerability to fluoxetine-induced indifference syndrome among opiate addicts: a case report.
    Bertschy G, Baumann P.
    Biol Psychiatry; 1995 Sep 15; 38(6):404-6. PubMed ID: 8547460
    [No Abstract] [Full Text] [Related]

  • 18. Fluoxetine (prozac) in depresion of adults.
    Kocur J, Rydzynski Z, Duszyk S, Gruszczynski W, Trendak W.
    Homeost Health Dis; 1991 Sep 15; 33(5-6):295. PubMed ID: 18265505
    [No Abstract] [Full Text] [Related]

  • 19. Fluoxetine-induced SIADH: most likely in the elderly?
    Burke D, Franker S.
    Aust N Z J Psychiatry; 1996 Apr 15; 30(2):299-301. PubMed ID: 8811278
    [No Abstract] [Full Text] [Related]

  • 20. Fluoxetine versus placebo in advanced cancer outpatients.
    Alliot C.
    J Clin Oncol; 2004 Jan 01; 22(1):204-5; author reply 206-8. PubMed ID: 14701790
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.